STOCK TITAN

Evotec Ag Stock Price, News & Analysis

EVO Nasdaq

Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.

Evotec AG (EVO) delivers cutting-edge solutions in drug discovery and development through strategic partnerships across the life sciences sector. This news hub provides investors and industry professionals with essential updates on the company’s progress in transforming biomedical research into therapeutic solutions.

Access real-time information on quarterly financial results, R&D collaborations, and manufacturing advancements from Evotec’s biologics division. Our curated collection includes updates on central nervous system research, oncology developments, and precision medicine initiatives that demonstrate the company’s leadership in pharmaceutical innovation.

Key updates cover regulatory milestones, technology platform enhancements, and global expansion efforts across Evotec’s European and U.S. facilities. Stay informed about partnerships driving novel therapies in metabolic diseases, infectious disease treatments, and next-generation biologics production.

Bookmark this page for streamlined access to Evotec’s latest achievements in bridging academic research-commercialization gap. Regularly updated content ensures you maintain strategic awareness of developments impacting the drug discovery ecosystem.

Rhea-AI Summary

Bayer and Evotec have updated their strategic collaboration to focus on developing innovative precision treatments for cardiovascular diseases. By leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs), the alliance aims to identify and validate novel targets to build a portfolio of precision cardiology therapeutics. Both companies will contribute drug targets and technology platforms for the development of innovative treatment options. Bayer will handle clinical development and commercialization while sharing responsibilities during pre-clinical development with Evotec. The collaboration seeks to address the high unmet medical need in cardiovascular diseases that are the leading cause of death globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
partnership
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none

FAQ

What is the current stock price of Evotec (EVO)?

The current stock price of Evotec (EVO) is $4.07 as of July 11, 2025.

What is the market cap of Evotec (EVO)?

The market cap of Evotec (EVO) is approximately 1.5B.
Evotec Ag

Nasdaq:EVO

EVO Rankings

EVO Stock Data

1.49B
355.26M
2.52%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg